Role of Taxanes in Lung-Cancer Chemotherapy

References

• Boring C, Squires T., Tong T, et al. Cancer Statistics. 1994. CA: A Cancer Journal Clinicians 1994; 44: 7–26
   PubMed Web of Science ®Google Scholar
• Grilli R, Oxman A, Julian J. Chemotherapy tor advanced non-small-cell lung cancer: how much benefit is enough?. J Clin Oncol 1993; 11: 1866–1871
   PubMed Web of Science ®Google Scholar
• Evans W K, Feld R, Murray N, et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med 1987; 107: 451–458
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83: 855–861
   PubMed Web of Science ®Google Scholar
• Roth B, Johnson D, Einhorn L, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10: 282–291
   PubMed Web of Science ®Google Scholar
• Chang A., Kim K, Glick J, et al. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993; 85: 388–394
   PubMed Web of Science ®Google Scholar
• Murphy W, Fossella F, Winn R, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993; 85: 384–388
   PubMed Web of Science ®Google Scholar
• Bonomi P, Kim K, Chang A, Johnson D. Phase III trial comparing etoposide (E) cisplatin (C) versus taxol (T) with cisplatin-G-CSF(G) versus taxol-cisplatin in advanced non-small cell lung cancer: an ECOG trial. Proc Am Soc Clin Oncol 1996; 15: 382
   Google Scholar
• Bonomi P D, Finkelstein D, Ruckdeschel J, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7: 1602–1613
   PubMed Web of Science ®Google Scholar
• Langer C., Leighton J, Comis R, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995; 13: 1860–1870
   PubMed Web of Science ®Google Scholar
• Johnson D, Paul D, Hande K, et al. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 1996; 14: 2054–2060
   PubMed Web of Science ®Google Scholar
• Bunn P. A., Jr, Kelly K. A phase I study of carboplatin and paclitaxel in nonsmall cell lung cancer. A University of Colorado Cancer Center study. Semin Oncol 1995; 22: 2–6
   PubMed Web of Science ®Google Scholar
• Belani C, Aisner J, Hiponia D, et al. Paclitaxel and carboplatin with or without filgastrim support in patients with metastatic non-small-cell lung cancer. Semin Oncol 1995; 22: 7–12
   PubMed Web of Science ®Google Scholar
• Giaccone G, Huizing M, Postmus P E, et al. Dose-finding and sequencing study of paclitaxel and carboplatin in non-small-cell lung cancer. Semin Oncol 1995; 22: 78–22
   PubMed Web of Science ®Google Scholar
• Rowinsky E K, Flood W A, Sartorius S E, et al. Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small-cell lung cancer. Semin Oncol 1995; 22: 48–54
   PubMed Web of Science ®Google Scholar
• Muggia F M, Vafai D, Natale R, et al. Paclitaxel 3-hour infusion given alone and combined with carboplatin: preliminary results of dose-escalation trials. Semin Oncol 1995; 22: 63–66
   PubMed Web of Science ®Google Scholar
• Hainsworth J D, Thompson F D, Greco F A. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol 1995; 13: 1609–1614
   PubMed Web of Science ®Google Scholar
• Hainsworth J D, Greco F A. Paclitaxel in lung cancer: 1-hour infusion given alone or in combination chemotherapy. Semin Oncol 1995; 22: 45–49
   PubMed Web of Science ®Google Scholar
• Langer C, Rosvold E, Millenson M, et al. Paclitaxel (P) by a 1 or 24 hour (HR) infusion combined with carboplatin (C) in advanced non-small-cell lung carcinoma (NSCLC): a comparative analysis. Proc Am Soc Clin Oncol 1997; 16: 452a
   Google Scholar
• Akerley W, Choy H, Glantz M, et al. Phase II trial of weekly paclitaxel for advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1997; 16: 450a
   Google Scholar
• Belani C P, Aisner J, Day R, et al. Weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy (TRT) for locally advanced non-small-cell lung cancer (NSCLC): three year follow-up. Proc Am Soc Clin Oncol 1997; 16: 448a
   Google Scholar
• Hudes R, Langer C, Movsas B, et al. Induction paclitaxel (Taxol) and carboplatin (CBDCA) followed by concurrent chemoradio-therapy (TRT-CT) in unresectable, locally advanced non-small-cell lung carcinoma (NSCLC): report of FCCC 94–001. Proc Am Soc Clin Oncol 1997; 16: 448a
   Google Scholar
• Choy H, Akerley W., Safran H, et al. Phase II trial of weekly paclitaxel, carboplatin and concurrent radiation therapy for locally advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1997; 16: 456a
   Google Scholar
• Niell H B, Miller A A, Kumar P, et al. Phase I/U trial of paclitaxel (TAX), cisplatin (DDP) and radiation therapy for stage III non-small-cell lung cancer. Proc Am Soc Clin Oncol 1997; 16: 447a
   Google Scholar
• Wagner H, Antonia S J, Williams C C, et al. Concurrent paclitaxel/ cisplatin (PC) with thoracic radiation (TR) in patients with stage IIIA/B non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1997; 16: 448a
   Google Scholar
• Cerny T, Kaplan S, Pavlidis N, et al. Docetaxel (Taxotere) is active in nonsmall cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG). Br J Cancer 1994; 70: 384–387
   PubMed Web of Science ®Google Scholar
• Francis P, Rigas J, Kris M, et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994; 12: 1232–1237
   PubMed Web of Science ®Google Scholar
• Fossella F, Lee J, Murphy W, et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994; 12: 1238–1244
   PubMed Web of Science ®Google Scholar
• Burris H., Eckardt J, Fields S, et al. Phase II trials of taxotere in patients with non-small-cell lung cancer. Proc Am Soc Clin Oncol 1993; 12: 335
   Google Scholar
• Miller V A, Rigas J R, Kile M G, et al. Phase II trial of docetaxel given at a dose of 75 mg/m2 with prednisone premedication in non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1994; 13: 364
   Google Scholar
• Watanabe K, Yokoyama A., Furuse K, et al. Phase II trial of docetaxel in previously untreated non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1994; 13: 331
   Google Scholar
• Kudo S, Hino M, Fujita A, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with non-small-cell lung cancer. Jpn J Cancer Chemother 1994; 21: 2617–2623
   PubMedGoogle Scholar
• Bishop J, Zalcberg J., Webster L, et al. A phase I trial of the combination Taxotere (docetaxel) and cisplatin in patients with advanced non-small-cell lung cancer. Lung Cancer 1994; 1l(suppl 1)124
   Google Scholar
• LeChevalier T, Belli L, Monnier A, et al. Phase II study of docetaxel (taxotere) and cisplatin in advanced nonsmall cell lung cancer (NSCLC): an interim analysis. Proc Am Soc Clin Oncol 1995; 14: 1059
   Google Scholar
• Zalcberg J R, Bishop J F, Millward M J, et al. Preliminary results of the first phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced nonsmall cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1995; 14: 1062
   Google Scholar
• Cole J T, Gralla R J, Marques C B, et al. Phase II study of cisplatin + docetaxel (taxotere) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1995; 14: 1087
   Google Scholar
• Fossella F V, Lee J S, Kau S W, et al. Docetaxel (D) for platinum-refractory nonsmall cell lung cancer (NSCLC): comparison of phase II results to historical controls (HC). Proc Am Soc Clin Oncol 1997; 16: 468a
   Google Scholar
• Gandara D R, Vokes E, Green M, et al. Docetaxel (Taxoere) in platinum-treated non-small cell lung cancer (NSCLC): confirmation of prolonged survival in a multicenter trial. Proc Am Soc Clin Oncol 1997; 16: 454a
   Google Scholar
• Ettinger D, Finkelstein D, Sarma R, et al. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1995; 13: 1430–1435
   PubMed Web of Science ®Google Scholar
• Jett J R, Kirschling R J, Jung S H, Group N CCT. A phase II trial of taxol and GCSF in previously untreated patients with extensive stage small cell lung cancer (SCC). Semin Oncol 1995; 22(suppl 3)75–77
   PubMed Web of Science ®Google Scholar
• Nair S, Marschke R, Grill J, et al. A phase II study of paclitaxel (Taxol) and cisplatin (CDDP) in the treatment of extensive stage small cell lung cancer (ESSCLC). Proc Am Soc Clin Oncol 1997; 16: 454a
   Google Scholar
• Hainsworth J D, Erland J, Peters M, et al. Treatment of small cell lung cancer (SCLC) with taxol (1-hr infusion), carboplatin, and etoposide: phase II study of an outpatient regimen. Proc Am Soc Clin Oncol 1994; 13: A1171
   Google Scholar
• Hainsworth J D, Stroup S L, Greco F A. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small eel! lung carcinoma. Cancer 1996; 77: 2458–2463
   PubMed Web of Science ®Google Scholar
• Bunn P J, Kelly K. A phase 1 study of carboplatin and paclitaxel in small-cell lung cancer: A University of Colorado Cancer Center study. Semin Oncol 1995; 22: 54–58
   PubMed Web of Science ®Google Scholar
• Glisson B S, Kurie J M, Fox N J, et al. Phase I-II study of cisplatin. etoposide, and paclitaxel (PET) in patients with extensive small cell lung cancer (ESCLC). Proc Am Soc Clin Oncol 1997; 16: 455a
   Google Scholar
• Georgiadis M S, Brown J E, Schuler B S, et al. Phase 1 study of a four-day continuous infusion of paclitaxel followed by cisplatin in patients with advanced lung cancer. Proc Am Soc Clin Oncol 1995; 14: A1072
   Google Scholar
• Strauss G M, Lynch T J, Elias A D, et al. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer. Semin Oncol 1995; 22: 70–74
   PubMed Web of Science ®Google Scholar
• Smyth J F, Smith I E, Sessa C, et al. Activity of docetaxel (taxot-ere) in small cell lung cancer. Eur J Cancer 1994; 30A: 1058–1060
   PubMed Web of Science ®Google Scholar